

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A composition comprising at least one peptide of eight to thirteen residues in length, said at least one peptide comprising a CTL epitope selected from the group consisting of:

DSVYGDTLER (SEQ ID NO: 527);
HTMLCMCCR (SEQ ID NO: 673);
LYNLLIRCF (SEQ ID NO: 846);
SVYGETLER (SEQ ID NO: 627);
LTEYVLDLY (SEQ ID NO: 139);
TFCCCKCDSTF (SEQ ID NO: 859);
AVCDKCLKFR (SEQ ID NO: 502);
ITDIILECVY (SEQ ID NO: 53);
LTDIEITCVY (SEQ ID NO: 55);
VYCKTVLEF (SEQ ID NO: 807); and
admixtures thereof.

2. (cancelled)
3. (cancelled)
4. (cancelled)
5. (cancelled)

6. (previously presented) The composition of claim 1, further comprising a spacer molecule, wherein said spacer molecule is linked to at least one of said one or more peptides.
7. (previously presented) The composition of claim 1, further comprising a carrier, wherein said carrier is admixed with or linked to at least one of said one or more peptides.
8. (cancelled).
9. (previously presented) The composition of claim 1, further comprising a lipid, wherein said lipid is admixed with or linked to at least one of said one or more peptides.
10. (previously presented) The composition of claim 1, wherein at least one of the one or more peptides are incorporated as part of a liposome.
11. (cancelled)
12. (cancelled)
13. (previously presented) The composition of claim 1, wherein at least one of the one or more peptides is a peptide from papilloma virus.
14. (cancelled)
15. (cancelled)
16. (cancelled)
17. (cancelled)
18. (cancelled)
19. (cancelled)
20. (previously presented) The composition of claim 1, wherein said CTL epitope is DSVYGDTLER (SEQ ID NO: 527).

21. (previously presented) The composition of claim 1, wherein said CTL epitope is HTMLCMCCR (SEQ ID NO: 673).
22. (previously presented) The composition of claim 1, wherein said CTL epitope is LYNLLIRCF (SEQ ID NO: 846).
23. (previously presented) The composition of claim 1, wherein said CTL epitope is SVYGETLER (SEQ ID NO: 627).
24. (previously presented) The composition of claim 1, wherein said CTL epitope is LTEYVLDLY (SEQ ID NO: 139).
25. (previously presented) The composition of claim 1, wherein said CTL epitope is TFCCCKCDSTF (SEQ ID NO: 859).
26. (previously presented) The composition of claim 1, wherein said CTL epitope is AVCDKCLKFR (SEQ ID NO: 502).
27. (previously presented) The composition of claim 1, wherein said CTL epitope is ITDIILECVY (SEQ ID NO: 53).
28. (previously presented) The composition of claim 1, wherein said CTL epitope is LTDIEITCVY (SEQ ID NO: 55).
29. (previously presented) The composition of claim 1, wherein said CTL epitope is VYCKTVLEF (SEQ ID NO: 807).
30. (new) A composition consisting essentially of at least one peptide of eight to thirteen residues in length, said at least one peptide comprising a CTL epitope selected from the group consisting of:

DSVYGDTLER (SEQ ID NO: 527);

HTMLCMCCR (SEQ ID NO: 673);

LYNLLIRCF (SEQ ID NO: 846);
SVYGETLER (SEQ ID NO: 627);
LTEYVLDLY (SEQ ID NO: 139);
TFCCCKCDSTF (SEQ ID NO: 859);
AVCDKCLKFR (SEQ ID NO: 502);
ITDIILECVY (SEQ ID NO: 53);
LTDIEITCVY (SEQ ID NO: 55);
VYCKTVLEF (SEQ ID NO: 807); and
admixtures thereof.